Conditions: Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase
Keywords: Chronic phase Chronic myelogenous leukemia CML Philadelphia chromosome positive Ph+ Nilotinib CML-CP Suboptimal molecular response
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 45
Healthy volunteers: no

Brief summary:
To evaluate the major molecular response (MMR) rate at 12 months of nilotinib treatment on study in patients with Philadelphia Chromosome Positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP) who have a suboptimal molecular response to imatinib at 18 months or later.

Detailed description:

Arms:
arm 1: 400 mg BID

Interventions: intervention 1: Nilotinib
Intervention descriptions: intervention 1: 400 mg BID

Protocol document: